2020Gene
Gaithersburg, US · 1 known investors
20/20 BioLabs develops laboratory blood tests using machine learning for the early detection of cancers and chronic diseases, including a multi-cancer early detection (MCED) protein tumor marker test and an inflammation biomarker test. Its tests use at-home upper-arm capillary blood collection and target individuals and healthcare providers.
Founders & leadership
JC
Jonathan CoheninCo-founder
MC
Mr. CohenFounder, CEO & President
AS
Anne ShiflettExecutive
JZ
Jiminy ZhouExecutive
DL
Dr. LebowitzChief Scientific Officer
MB
Mr. BergmanChief Financial Officer
Board
JK
Joel KanterBoard director
PR
Prasanth ReddyBoard director
JG
John G ComptonBoard director
JW
John W. RollinsBoard director
WL
Wei LuBoard director
RM
Richard M. CohenBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$4.6M disclosed across 3 rounds · 2014–2025
▶$70KraisedFeb 2025 · 3 investors · BiotechnologyRule 506(b)
▶$70KraisedFeb 2025 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan CohenExecutive Officer, Director
- Prasanth ReddyDirector
- John G ComptonDirector
- John W. RollinsDirector
- Wei LuDirector
- Richard M. CohenDirector
- Anne ShiflettExecutive Officer
- Jiminy ZhouExecutive Officer
- Michael A RossDirector
- Offering amount
- $3M
- Amount sold
- $70K
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedFeb 2016 · 66 investors · BiotechnologyRule 506(c)
▶$2.5MraisedFeb 2016 · 66 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Jonathan CohenExecutive Officer, Director
- Caroline PopperDirector
- Dean HautamakiDirector
- Vladimir KnezevicDirector
- Donald WallachDirector
- Joel KanterExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $2.5M
- Minimum investment
- $5K
- Sales commissions
- $37.1K
- Placement agents
- LBMZ Securities, Inc.
- First sale
- Oct 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$2MraisedFeb 2016 · 1 investors · BiotechnologyRule 506(b)
▶$2MraisedFeb 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Vladimir KnezevicDirector
- Caroline PopperDirector
- Joel KanterExecutive Officer, Director
- Donald WallachDirector
- Jonathan CohenExecutive Officer, Director
- Dean HautamakiDirector
- Offering amount
- $3M
- Amount sold
- $2M
- Minimum investment
- $50K
- Proceeds to insiders
- $150K
- First sale
- Jan 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 17 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $750K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2010 | $2.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $199.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $217.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $183.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2008 | $649.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2007 | $165.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2007 | $117.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2006 | $177.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2006 | $177.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2004 | $100K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | $100K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | $99.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | $96.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | $96.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | $79.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2003 | $97.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does 2020Gene do?
- 20/20 BioLabs develops laboratory blood tests using machine learning for the early detection of cancers and chronic diseases, including a multi-cancer early detection (MCED) protein tumor marker test and an inflammation biomarker test. Its tests use at-home upper-arm capillary blood collection and target individuals and healthcare providers.
- Who founded 2020Gene?
- 2020Gene was founded by Jonathan Cohen, Mr. Cohen.
- Who are 2020Gene's investors?
- 2020Gene's investors include Keiretsu Forum.
- How much funding has 2020Gene raised?
- 2020Gene has disclosed $4.6M raised across 3 rounds.
- Where is 2020Gene headquartered?
- 2020Gene is headquartered in Gaithersburg, US.